COMMUNIQUÉS West-GlobeNewswire

Ambu A/S: Ambu launches ambitious strategy towards 2020

04/10/2017 - 10:58

After exceeding the goals of the 2017 strategy, Ambu sets new goals and aims to double revenue in just three years. The key elements are a stable core business and disruptive single-use endoscopy technology. In 2013, [...]

Immunocore Appoints Andrew Hotchkiss as Chief Commercial Officer

04/10/2017 - 08:00

PRESS RELEASE Immunocore Appoints Andrew Hotchkiss as Chief Commercial Officer (Oxford, UK and Conshohocken, US, 4 October 2017) Immunocore Limited, the world's leading TCR company developing biological drugs to treat [...]

XBiotech annonce l'ajout du dermatologue renommé, le Dr William Levis, à son Conseil scientifique consultatif

04/10/2017 - 02:48

AUSTIN, Texas, le 4 octobre 2017 (GLOBE NEWSWIRE). - XBiotech Inc. (NASDAQ : XBIT) est heureuse d'annoncer la nomination de William Levis, MD, à son Conseil scientifique consultatif (Scientific Advisory Board - SAB). Le [...]

KARO PHARMA AB'S TAKEOVER OFFER FOR WEIFA ASA SUCCESSFUL

03/10/2017 - 18:00

On expiration of the offer period on 3 October, 2017 at 16:30 CEST, Karo Pharma AB ("Karo Pharma") had received acceptances for the voluntary offer ("Voluntary Offer") to acquire all shares in Weifa ASA ("Weifa") for a [...]

NICOX : Nombre total de droits de vote au 30 septembre 2017

03/10/2017 - 17:45

Nicox SA Société anonyme au capital de 29 169 338 euros Siège social : DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 Le 3 octobre 2017, PUBLICATION MENSUELLE DU NOMBRE D' [...]

NICOX : Number of voting rights as of September 30, 2017

03/10/2017 - 17:45

Nicox SA Société anonyme with a registered capital of € 29,169,338 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On October 3, 2017, MONTHLY PUBLICATION OF THE [...]

Targovax granted US Patent for mutant-RAS neoantigen platform 2nd generation product TG02

03/10/2017 - 14:48

Extends IP protection of TG02 in the US until 09.12.2034 Oslo, 3 October 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target [...]

Advanced Bifurcation Systems Announces Plan for Human Clinical Trials in New Brunswick, Canada

03/10/2017 - 13:55

LOS ANGELES, Oct. 03, 2017 (GLOBE NEWSWIRE) -- Advanced Bifurcation Systems ("ABS" or the "Company"), a clinical stage medical device company developing an innovative stenting platform which overcomes the limitations of [...]

RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA® in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

03/10/2017 - 13:39

BEKINDA ® i 12 mg Phase II study successfully met its primary endpoint, improving primary efficacy outcome of stool consistency by an absolute difference of 19.4% vs. placebo and comparing favorably with previously [...]

Shire plc : Director/PDMR Shareholding

03/10/2017 - 13:00

Director/PDMR Shareholding October 3, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) Notification of transactions by persons discharging managerial responsibilities 1. Details of the person discharging managerial [...]

Saniona AB: Saniona obtains research milestone from The Michael J. Fox Foundation for Parkinson's Research

03/10/2017 - 12:45

PRESS RELEASE October 3, 2017 Saniona, a leading biotech company in the field of ion channels, today announces that it has reached the third research milestone for identifying new drug candidates for the treatment of [...]

Summit Therapeutics plc : Exercise of Options

03/10/2017 - 12:15

Summit Therapeutics plc ("Summit" or the "Company") EXERCISE OF SHARE OPTIONS Oxford, UK, 3 October 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing [...]

AC Immune Awarded Continuation of 2015 Grant from The Michael J. Fox Foundation for Parkinson's Research

03/10/2017 - 10:53

Continued development of PET tracer for earlier and more accurate diagnosis of Parkinson's disease Focuses on alpha-synuclein, a key protein in Parkinson's disease pathology Lausanne, Switzerland, - October 3, 2017 - AC [...]

Amer Sports third quarter 2017 results published on October 26

03/10/2017 - 09:30

Amer Sports Corporation PRESS RELEASE October 3, 2017 at 10:30 a.m. Amer Sports third quarter 2017 results published on October 26 Amer Sports Corporation will publish its third quarter 2017 results on Thursday, October [...]

PharmaMar will participate at the 17th European Large & MidCap Event to be held in Paris

03/10/2017 - 09:00

On October 4 th and 5th, PharmaMar will meet with European investors to increase awareness of the Company and to explain in detail present and future projects. This 17th annual event will host 400 international [...]

Solon Eiendom ASA :Primary insider notification

03/10/2017 - 08:30

(Oslo, Norway, 2 October 2017) Solon Eiendom ASA Board Member Tore Aksel Voldberg (through his wholly owned company Skøien AS) has today bought 10 587 shares in Solon Eiendom ASA at a price of NOK 18,5000. Following [...]

Santhera Presents Data and Hosts Symposium on Respiratory Function Decline in Duchenne Muscular Dystrophy at the World Muscle Society Congress

03/10/2017 - 07:00

Liestal, Switzerland, October 3, 2017 - Santhera Pharmaceuticals (SIX: SANN) announces that it will present additional data from the positive Phase III DELOS trial in patients with Duchenne muscular dystrophy (DMD) at [...]

ABLYNX FILES REGISTRATION STATEMENT FOR A PROPOSED GLOBAL OFFERING

02/10/2017 - 23:06

REGULATED INFORMATION - INSIDE INFORMATION GHENT, Belgium, 2 October 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] , a late-stage clinical biopharmaceutical company utilising its proprietary Nanobody® platform to [...]

Nightstar Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares

02/10/2017 - 22:05

LEXINGTON, Mass. and LONDON, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc ("Nightstar" or the "Company") (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited [...]